Mycophen

Mycophen Dosage/Direction for Use

mycophenolic acid

Manufacturer:

Micro Labs

Distributor:

Zizawa Healthcare
Full Prescribing Info
Dosage/Direction for Use
Renal Transplant: Adults: Mycophenolate should be initiated within 72 hrs following transplantation. The recommended dose is 1 g administered twice daily (2 g daily dose).
Children and Adolescents 2-18 years: 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). Children <2 years: Not recommended.
Cardiac Transplant: Adults: Mycophenolate should be initiated within 5 days following transplantation. The recommended dose is 1.5 g administered twice daily (3 g daily dose). Children: No data are available for pediatric cardiac transplant patients.
Hepatic Transplant: Adults: Mycophenolate IV should be administered for the first 4 days following hepatic transplant with oral mycophenolate initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose). Children: No data are available for pediatric transplant patients.
Use in elderly (65 years): 1 g administered twice daily for renal transplant patients and 1.5 g twice daily for cardiac or hepatic transplant patients is appropriate for the elderly.
Renal Impairment: In renal transplant patients with severe chronic renal impairment (glomerular filtration rate <25 mL·min-1·1.73 m-2), outside the immediate post-transplant period, doses >1 g administered twice daily should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delay renal graft function post-operatively. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.
Severe Hepatic Impairment: No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.
Treatment During Rejection Episodes: Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of mycophenolate is not required. There is no basis for mycophenolate dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in